IceCure Medical Ltd. Ordinary Shares (ICCM)
Stock · NASDAQ · Health Care
$1.06as of 10/16/2026
Price chart
ICCM Signal Track Record
How signals performed across all stocks →What ICCM's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 24 | +2.5% | 58% | October 6, 2026 |
| Volume Spike | 24 | -8.1% | 38% | September 29, 2026 |
| Bollinger Band Breakout | 20 | -12.8% | 15% | June 24, 2026 |
| 200-Day Moving Average TouchActive now | 10 | -11.7% | 20% | September 2, 2025 |
| Any 20-session window (baseline) | -5.3% | 35% |
Computed by MarketWall from daily closing prices since June 10, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ICCM
IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposable…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 67
- Website
- icecure-medical.com/
Fundamentals
- 1-day range
- $1.03$1.13
- Market cap
- $10.55M
- P/E (trailing)
- —
- P/E (forward)
- -0.33
- EPS (trailing)
- $-6.73
- Dividend yield
- —
- Beta
- 0.43
- Avg. volume
- 138.9K
Forecasts
3 analyst ratings
IceCure Medical Ltd. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- ICCMIceCure Medical Ltd. Ordinary Shares$1.06▲ 1.92%Market cap $10.55MP/E —$1.04$29.46
- SINTSiNtx Technologies Inc. Common Stock$1.74▼ 1.69%Market cap $10.36MP/E —$1.4$4.5
- MODDModular Medical Inc. Common Stock$2.32▲ 7.18%Market cap $10.99MP/E —$1.72$18.76
- CODXCo-Diagnostics Inc. Common Stock$0.654▼ 8.53%Market cap $9.91MP/E —$0.746$46.5
- AMIXAutonomix Medical Inc. Common Stock$2.85▼ 2.90%Market cap $11.82MP/E —$2.44$32.55
- ICUSeaStar Medical Holding Corporation Common Stock$2.9▼ 5.23%Market cap $12.19MP/E —$2.07$7.35
- FEMYFemasys Inc. Common Stock$1.65▼ 4.90%Market cap $8.91MP/E —$1.67$22.2
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ICCM IceCure Medical Ltd. Ordinary Shares | $10.55M | — | $1.06 | ▲ 1.92% | $1.04$29.46 |
| SINT SiNtx Technologies Inc. Common Stock | $10.36M | — | $1.74 | ▼ 1.69% | $1.4$4.5 |
| MODD Modular Medical Inc. Common Stock | $10.99M | — | $2.32 | ▲ 7.18% | $1.72$18.76 |
| CODX Co-Diagnostics Inc. Common Stock | $9.91M | — | $0.654 | ▼ 8.53% | $0.746$46.5 |
| AMIX Autonomix Medical Inc. Common Stock | $11.82M | — | $2.85 | ▼ 2.90% | $2.44$32.55 |
| ICU SeaStar Medical Holding Corporation Common Stock | $12.19M | — | $2.9 | ▼ 5.23% | $2.07$7.35 |
| FEMY Femasys Inc. Common Stock | $8.91M | — | $1.65 | ▼ 4.90% | $1.67$22.2 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Full Transcript: Icecure Medical Q2 2026 Earnings CallBenzinga · 9/18/2026
- IceCure Secures China NMPA Approval for ProSense Cryoablation SystemYahoo · 9/11/2026
Insider Activity
Insider Actions →- Good Shad · August 14, 2026 · Grant131.5K
- Tel-Tzure Tlalit Bussi · August 14, 2026 · Grant101.5K
- Levav Shay · August 14, 2026 · Grant141.5K
- Dotan Merav Nir · August 14, 2026 · Grant73.9K
- Peleg Meir · August 14, 2026 · Grant181.5K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
ICCM Adds Legacy Health Site for Prosense Cryoablation Study
IceCure Medical announced it has added Legacy Health in Portland, Oregon, as a new U.S. clinical site for its post‑marketing ChoICE study of Prosense Cryoablation. The expansion increases the number of patients enrolled in the low‑risk breast cancer trial, which could provide more robust safety and efficacy data. The study is part of the company’s effort to support the market launch of its cryoablation technology. The addition is a routine development in the company’s clinical program.
ICCM Adds Legacy Health Site for Prosense Cryoablation Study. IceCure Medical announced it has added Legacy Health in Portland, Oregon, as a new U.S. clinical site for its post‑marketing ChoICE study of Prosense Cryoablation. The expansion increases the number of patients enrolled in the low‑risk breast cancer trial, which could provide more robust safety and efficacy data. The study is part of the company’s effort to support the market launch of its cryoablation technology. The addition is a routine development in the company’s clinical program.